When is CGEN's next earnings date?

Based on SEC filing cadence, Compugen Ltd. (CGEN)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is CGEN stock expected to move on earnings?

Volatility modeling currently projects a ±11% event move for CGEN, spanning a range between $1.76 and $2.2.

Stock Ratings / Health Care / CGEN / earnings

DTIL (30) PALI (32) IVVD (23) ARTV (27) ⌘ Pro Terminal →

Compugen Ltd. (CGEN) Next Earnings Date & Expected ±11% Move

$1.98 0.00% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.98

Compugen Ltd. (CGEN) carries a Roarable Rating of C (Hold) with 63/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C • HOLD / WATCH Cap $187.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CGEN Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CGEN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Compugen Ltd. (NASDAQ: CGEN) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 63/100 at a spot price of $1.98 (0.00% 1D, market cap $187.3M). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 15/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 19/20. Across 1015 tracked Health Care issuers, CGEN ranks #143 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CGEN compare to DTIL and PALI in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CGEN carries a Roarable C (63/100 RQD), trailing P/E of 5.5x, gross margin of 87.3%, and ROIC of 85.0%. By comparison, DTIL (Precision BioSciences Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $194.9M) and PALI (Palisade Bio Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $202.2M). Among the 5-stock peer group, CGEN leads on earnings multiple (5.5x) while CGEN leads on capital efficiency (85.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CGEN?

▼

Per CGEN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001119774), Compugen Ltd. generated $72.8M in revenue (+161.1% YoY), $35.3M in net income, and $31.3M in free cash flow against $156.6M in total assets and $0 in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.98 (-0.19%)🧬 Cannibal Buyback (-3.20% YoY Shares)⚙️ Cash Engine: 14/20 (B-) • 43.1% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 63/100 (C) historically posted market-perform odds over rolling 90-day windows (+0.9% avg 90D alpha vs SPY • 54.8% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE+2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CGEN)Realized 20D OHLCV Swing Band: ±11%

Deterministic 5-Pillar Attribution (63/100 Composite)

🔍 WHY CGEN SCORES 63/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Insider Conviction & Share Dilution+19/20 pts (30% of score)

SEC Form 4 / 13F Thermometer: 86% Net Buy • Cannibal Buyback (-3.20% YoY Shares)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+15/20 pts (24% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B$2.07-4.8% Next Q

Q2 (-2Q)

Grade B-$1.97-4.6% Next Q

Q3 (-1Q)

Grade B-$1.88+5.3% Next Q

Current

Grade C$1.98+0.9% Hist 90D α

Trajectory: B (71) → C (63)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the CGEN Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 63/100 (C) score, CGEN faces multiple-compression risk if 5.5x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-3.20% YoY Shares) — any gross margin slip below 84.8% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($2.31) or 200D SMA ($2.30) invalidates the momentum regime and cuts Target Base ($2.02) toward Bear Floor ($1.58).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CGEN• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CGEN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 63%NO 37%Trade / Inspect Odds →

NEXT EST. WINDOW: Dec 30, 2026 (~56 DAYS)

Historical OHLCV Volatility ±11% Swing Band

±$0.22 Expected Swing

MODEL EARNINGS SETUP GAUGE

CGEN Quantitative Pre-Earnings Setup: 63/100

Trailing EPS: $0.37 • YoY Revenue Growth: 161.1%

Model Bullish Setup (63/100)Model Risk Weight (37/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$72.8M	$35.3M	$31.3M	87.3%
FY 2024	2024-12-31	$27.9M	-$14.2M	$49.5M	71.5%
FY 2023	2023-12-31	$33.5M	-$18.8M	-$35.9M	87.3%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating CGEN & AI Leaders Without Chasing Tops

✓Institutional whale strikes & implied earnings move audit on CGEN
✓How disciplined traders manage risk using pre-published trigger & invalidation levels
✓Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CGEN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -25.00%▼ DESCENDING CHANNEL

2026-11-03O $2.04H $2.04L $1.98C $1.98VOL 255.5K

RES: $2.87SUP: $1.83SMA50: $2.31SMA200: $2.30

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CGEN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CGEN Butterfly Map → + Track CGEN →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

-12.3%/yr Implied 5Y Growth

vs. +161.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on CGEN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CGEN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CGEN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CGEN)

Health Care Rank #143 of 1015 ⚔️ DTIL vs CGEN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CGEN vs. DTIL, PALI, IVVD, ARTV)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Compugen Ltd. (CGEN) ranks #143 by composite RQD confidence (63/100, grade C) and #580 by equity capitalization ($187.3M). Within this direct 5-issuer industry benchmark cohort, CGEN leads on earnings valuation at 5.5x trailing P/E, while CGEN leads on capital efficiency and profitability with 85.0% ROIC and 87.3% gross margin. CGEN currently leads its immediate peer cohort in composite quantitative strength at 63/100 (C).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CGEN ACTIVE Compugen Ltd.	C	63/100	5.5x	87.3%	85.0%	0.00%	$187.3M	Benchmark Subject
DTIL Precision BioSciences Inc.	E	30/100	—	—	-35.0%	-1.56%	$194.9M	/dtil-vs-cgen →
PALI Palisade Bio Inc.	E	32/100	—	—	-35.0%	-3.45%	$202.2M	/pali-vs-cgen →
IVVD Invivyd Inc.	E	23/100	—	—	-35.0%	+0.05%	$171.5M	/ivvd-vs-cgen →
ARTV Artiva Biotherapeutics Inc.	E	27/100	—	—	-35.0%	0.00%	$204.8M	/artv-vs-cgen →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001119774 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Compugen Ltd. (CGEN) reported GAAP revenue of $72.8M (+161.1% vs. FY2024 revenue of $27.9M , and +117.5% cumulative change since FY2023) , GAAP net income of $35.3M, operating cash flow of $31.6M, and free cash flow of $31.3M (-36.7% YoY). On the balance sheet, CGEN closed FY2025 with $156.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$72.8M	$35.3M	$31.6M	$31.3M	$156.6M	—
FY2024 (FY)	2024-12-31	$27.9M	-$14.2M	$49.6M	$49.5M	$115.0M	—
FY2023 (FY)	2023-12-31	$33.5M	-$18.8M	-$35.9M	-$35.9M	—	—

3. CGEN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CGEN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does CGEN compare to DTIL and PALI in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for CGEN?

Where is CGEN trading relative to its 50-day, 200-day, and 52-week technical levels?

CGEN last traded at $1.98 (0.00% on volume of 151,476 shares), positioning the stock -14.29% below its 50-day simple moving average ($2.31) and -13.91% below its 200-day simple moving average ($2.30). Across its 52-week range of $1.43 to $3.24, CGEN sits at the 30.4% percentile with a 14-day RSI of 41.1 (NEUTRAL RANGE) and an implied next-earnings move of ±11.0% ($1.76 to $2.20).

Direct Sub-Reports: CGEN RQD Cockpit CGEN 12M Forecast CGEN Earnings & Move CGEN Dividends & DRIP CGEN Insiders & 13F CGEN Whale Options CGEN Profit Sankey CGEN News & Why

ROARABLE RATING BRIEF • RQD 63/100 (C) ✓ SEC XBRL & RQD VERIFIED

CGEN — Compugen Ltd.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Compugen Ltd. (CGEN) earns a live Roarable RQD composite score of 63/100, corresponding to a C letter grade (Roarable Hold) at a spot price of $1.98 (0.00% 1D, market capitalization $187.3M).

Fundamental Cash Engine (14/20): Anchored by return on invested capital (ROIC) of 85.0%, gross margin of 87.3%, operating margin of 43.1%, and free cash flow yield of 16.24%.
Whale 13F & Options Flow (4/20) + Insider Conviction (19/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (11/20) + Forensic Balance Sheet (15/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 7/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Compugen Ltd. (CGEN) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry..2B. Per the market data, gross margin is 87.3%, operating margin is 43.1%, and net margin is 48.6%.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Compugen Ltd. (CGEN) reported $72.8M in annual revenue (up from $27.9M in FY2024, +161.1% YoY) and $35.3M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($33.5M revenue, -$18.8M net income) through FY2025, CGEN scaled operating cash flow to $31.6M and free cash flow to $31.3M, backed by $156.6M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (C • RQD 63/100): Company leadership has skin in the game with net positive insider conviction. Clean SEC annual filing review with no major hidden accounting time-bombs. With Fundamental Cash Engine at 14/20 and Institutional Whale Flow at 4/20, sustained execution supports upside toward the upper end of the $1.43 – $3.24 52-week range.
🐻 Primary Bear Case & Valuation Risk: Broader market pullbacks can still drag down strong stocks in the short run. Investors must weigh 5.5x trailing P/E and 3.2x EV/EBITDA against 43.1% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), CGEN carries a macro regime beta of 1.00 and gross margin of 87.3%.

Key Question #1: Can CGEN sustain or expand its 43.1% operating margin and 85.0% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $72.8M and free cash flow of $31.3M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is CGEN's 4.6x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

CGEN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Compugen Ltd. (CGEN) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CGEN Debate Forum (3) ↓

🟡 MARKET WIRE StockInvest.us • 21h ago

Compugen Stock Price Forecast. Should You Buy CGEN?

StockInvest.us report covering Compugen Ltd. (CGEN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Compugen to Participate in a Fireside Chat at the H.C. Wainwright 3rd Annual AI Based Drug Discovery & Development Conference

Yahoo Finance report covering Compugen Ltd. (CGEN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com • 1d ago

Stifel reiterates Compugen stock rating on ovarian trial update

Investing.com report covering Compugen Ltd. (CGEN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Compugen to Release Third Quarter 2026 Results on Monday, November 9, 2026

Yahoo Finance report covering Compugen Ltd. (CGEN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST https://www.siam.in/ • 1d ago

Locafy Limited (LCFY) Slips 6.55% to $1.14 as Shares Press Toward Lower Support - Momentum Surge Alerts

https://www.siam.in/ report covering Compugen Ltd. (CGEN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 22d ago

HC Wainwright & Co. Reiterates Buy on Compugen, Maintains $4 Price Target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Compugen (NASDAQ:CGEN) with a Buy and maintains $4 price target.

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 15h ago

BioMarin Pharmaceutical (BMRN) Q3 Earnings Surpass Estimates

BioMarin (BMRN) delivered earnings and revenue surprises of +355.56% and -0.23%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CGEN Bull vs. Bear Conversation Board — What's Your Call at $1.98?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CGEN 🐻 33% BEARISH CONVICTION

QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $2.30 (+16.2%)

📌 Pinned Debate

Per the RQD rating, an 85% ROIC, 16.24% FCF yield, and a swing to $35.3M net income in FY 2025 point to a strong cash engine on a 5.5 P

Picked up a starter position in CGEN in my $100K Virtual Cash book at $1.98. Per the RQD rating, an 85% ROIC, 16.24% FCF yield, and a swing to $35.3M net income in FY 2025 point to a strong cash engine on a 5.5 P/E.. Trading inside a $1.43–$3.24 52-week range with 16.24% FCF yield gives solid downside support if Biotechnology: Biological Products (No Diagnostic Substances) multiples expand this quarter.

SectorRotator 🐂 BULL

@QuantViper Agree on the RQD 63/100 quality, though with 1.0 beta I'm scaling in with half-size at $1.98 and keeping dry powder in case we test $1.84.

ME MeanReversion_88 RQD DEBATE OPENER • Quantitative Statistical Arb 🐻 BEARISH 🎯 Target: $1.58 (-20.2%)

Spot @ $1.98

Valuation & margin reality check on CGEN at $1.98 before chasing here

Careful chasing CGEN at $1.98. Valuation & margin reality check on CGEN at $1.98 before chasing here. Gross margin is 87.3%, but operating margin is 43.1%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $1.58 on multiple compression.